![Cheng Liu](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Cheng Liu
Amministratore Delegato presso
ESTRELLA IMMUNOPHARMA, INC.
Patrimonio netto: 1 M $ in data 31/07/2026
Profilo
Cheng Liu is the founder of Eureka Therapeutics, Inc., founded in 2006, holding the titles of Chairman, President & Chief Executive Officer.
Dr. Liu is also the founder of InvisiShield Technologies Ltd.,Estrella Biopharma, Inc...
Dr. Liu is currently President, Chief Executive Officer & Director at Estrella Immunopharma, Inc. since 2024.
Former positions include Chairman at JW (Cayman) Therapeutics Co. Ltd. from 2025 to 2026, Principal Scientist at Chiron Corp., and Member-Adversary & Executive Committee at SAPA-West from 1998 to 2007.
Education includes undergraduate and graduate degrees from Peking University and a doctorate from the University of California, Berkeley.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 31/12/2024 | 5.764.582 ( 1,38% ) | 1 M $ | 31/07/2026 | |
| 20/05/2026 | 297.437 ( 0,69% ) | 212 370 $ | 31/07/2026 |
Posizioni attive di Cheng Liu
| Società | Posizione | Inizio |
|---|---|---|
| ESTRELLA IMMUNOPHARMA, INC. | Amministratore Delegato | - |
Eureka Therapeutics, Inc.
 Eureka Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops T-cell therapies for cancer patients with solid tumors | Amministratore Delegato | - |
InvisiShield Technologies Ltd.
 InvisiShield Technologies Ltd. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company | Amministratore Delegato | - |
Estrella Biopharma, Inc.
 Estrella Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Develops and produces medicines for hematological cancers & tumors | Fondatore | - |
Precedenti posizioni note di Cheng Liu
| Società | Posizione | Fine |
|---|---|---|
| JW (CAYMAN) THERAPEUTICS CO. LTD | Presidente | 26/06/2026 |
SAPA-West | Corporate Officer/Principal | 01/01/2007 |
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Provides nucleic acid test for blood screening | Corporate Officer/Principal | - |
Formazione di Cheng Liu
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
41
Relazioni di 1° grado
9
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 9 |
|---|---|
Chiron Corp.
Chiron Corp. Medical SpecialtiesHealth Technology Provides nucleic acid test for blood screening | Health Technology |
Eureka Therapeutics, Inc.
Eureka Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops T-cell therapies for cancer patients with solid tumors | Health Technology |
Peking University
 Peking University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
SAPA-West | |
JW (Cayman) Therapeutics Co. Ltd.
 JW (Cayman) Therapeutics Co. Ltd. BiotechnologyHealth Technology Operates as biotechnology company that develops and manufactures cell immunotherapy products | Health Technology |
InvisiShield Technologies Ltd.
InvisiShield Technologies Ltd. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company | Commercial Services |
Estrella Biopharma, Inc.
Estrella Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Develops and produces medicines for hematological cancers & tumors | Health Technology |
Estrella Immunopharma, Inc.
 Estrella Immunopharma, Inc. BiotechnologyHealth Technology Operates as a preclinical-stage biopharmaceutical company focusing on cancer therapeutics to address treatment of blood cancers and solid tumors | Health Technology |
